Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula

Get In Touch

Quick Email
info.help@gmail.com
  • Home |
  • Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

Theravance halves headcount, ends all R&D work after phase 3 rare disease fail

  • March 3, 2026

Theravance Biopharma will lay off 50% of its workforce, end all R&D work and scrap a blood pressure disorder drug that failed a crucial phase 3 test.

Leave A Comment

Fields (*) Mark are Required